Immvira Refiles HKEX Listing Application, Citi and CICC Appointed Joint Sponsors
NewTimeSpace News: Immvira Bioscience Inc. refiled its listing application with HKEX on 16 July, with Citi and CICC acting as joint sponsors. Founded in 2015, the biotech firm focuses on R&D of oncolytic immunotherapies and engineered exosome therapeutics. Its core asset MVR-T3011, a novel HSV-1-based oncolytic immunotherapy in Phase II development, covers full-spectrum bladder cancer and head and neck squamous cell carcinoma among other indications.
NewTimeSpace News: Immvira Bioscience Inc. refiled its listing application to The Stock Exchange of Hong Kong Limited on 16 July 2026, with Citi and China International Capital Corporation (CICC) serving as joint sponsors.
Founded in 2015, the Company is a clinical-demand-driven biotechnology enterprise dedicated to the discovery, development, manufacturing and commercialisation of novel oncolytic immunotherapies and engineered exosome therapeutics. As of the latest practicable date, the Group has built a dual pipeline portfolio comprising two oncolytic immunotherapy candidates for solid tumours and five engineered exosome products with clinical prospects or direct commercialisation potential.
MVR-T3011, the flagship asset, is a novel herpes simplex virus type 1 (HSV-1) oncolytic immunotherapy candidate currently in Phase II clinical development. It integrates potent oncolytic activity with the expression of anti-PD-1 antibody and IL-12. The product is being evaluated both as monotherapy and combination regimen across a full spectrum of bladder cancer indications (including first-line and second-line treatment for high-risk NMIBC, neoadjuvant or adjuvant chemotherapy for MIBC), as well as third-line therapy for head and neck squamous cell carcinoma.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- Immvira Hong Kong IPO Application Lapses, Lead Asset MVR-T3011 Covers Full Spectrum of Bladder Cancer
- Csop Samsung Electronics Daily (2x) Leveraged Product (07747.HK) Fell 19.30% in Morning Trade, AUM at HKD 14.028 Billion
- CSOP SK Hynix Daily (2x) Leveraged Product (07709.HK) Fell 18.20% in Morning Trade, Turnover at HKD 3.219 Billion
- Wanjia Hang Seng Internet Technology Industry ETF Initiating Feeder Fund-A (018475) Rises Over 10% Since July as Zhipu's ARR Reaches US$1 Billion, Completing Its Full-Year Target Ahead of Schedule
- Premia China STAR50 ETF (03151.HK) Fell 3.55% in Morning Trade, AUM at HKD 940 Million
